PCOS in Adolescence and Type 2 Diabetes

Current Diabetes Reports

Volumn 15, Issue 1, 2015, Pages

  Carreau, Anne Marie ^a   Baillargeon, Jean Patrice ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Adolescents; Insulin resistance; Lipotoxicity; Polycystic ovaries syndrome; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIAZOXIDE; FLUTAMIDE; GESTAGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADOLESCENT; BLOOD PRESSURE; DYSGLYCEMIA; FEMALE; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOTOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PREVALENCE; REVIEW; SCREENING; WAIST CIRCUMFERENCE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; HIRSUTISM; HYPERINSULINISM; LIPID METABOLISM; METABOLISM; POLYCYSTIC OVARY SYNDROME; RISK FACTOR; VAGINA;

ADOLESCENT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; LIPID METABOLISM; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; VAGINA;

EID: 84938291286     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0564-3     Document Type: Review

References (100)

1. Trent ME et al. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2002;156(6):556–60.
2. Jones GL et al. Health-related quality of life among adolescents with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2011;40(5):577–88.
3. Zawadski, J.D., A., Diagnostic criteria for polycystic ovary syndrome: towards a rational approach, in Polycystic Ovary Syndrome., J.R.H. Dunaif A. Givens, F., Editor. 1992, Blackwell Scientific: Oxford, England. p. 377–384.
4. Rotterdam, E.A.-S.P.c.w.g. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.
5. Azziz R et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–45.
6. Legro RS et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92.
7. Hardy TS, Norman RJ. Diagnosis of adolescent polycystic ovary syndrome. Steroids. 2013;78(8):751–4.
8. Rosenfield RL. Clinical review: Adolescent anovulation: Maturational mechanisms and implications. J Clin Endocrinol Metab. 2013;98(9):3572–83.
9. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203(3):201 e1–5.
10. Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril. 2006;86 Suppl 1:S6.
11. Hickey M et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: Implications for diagnosis. Hum Reprod. 2011;26(6):1469–77.
12. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7.
13. Diamanti-Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol. 2010;24(2):173–83.
14. Biro FM, Emans SJ. Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. J Adolesc Health. 2008;43(2):103–5.
15. Lucky AW et al. The prevalence of upper lip hair in black and white girls during puberty: A new standard. J Pediatr. 2001;138(1):134–6.
16. Knochenhauer ES et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab. 1998;83(9):3078–82.
17. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab. 2006;91(10):3786–90.
18. Kristensen SL et al. A very large proportion of young Danish women have polycystic ovaries: Is a revision of the Rotterdam criteria needed? Hum Reprod. 2010;25(12):3117–22.
19. Codner E et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril. 2011;95(2):702–6. e1–2.
20. Diamanti-Kandarakis E et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84(11):4006–11.
21. Michelmore KF et al. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf). 1999;51(6):779–86.
22. Asuncion M et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434–8.
23. Azziz R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9.
24. Christensen SB et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013;100(2):470–7.
25. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(1):162–8.
26. Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(6):E1088–96.
27. Kamel N et al. Role of ovary and adrenal glands in hyperandrogenemia in patients with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113(2):115–21.
28. Azziz R et al. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1998;83(7):2317–23.
29. Franks S, Gharani N, Gilling-Smith C. Polycystic ovary syndrome: Evidence for a primary disorder of ovarian steroidogenesis. J Steroid Biochem Mol Biol. 1999;69(1–6):269–72.
30. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003;46(2):325–40.
31. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.
32. Lewy VD et al. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138(1):38–44.
33. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84(4):1470–4.
34. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2011;24(3):161–5.
35. Hoeger K et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93(11):4299–306.
36. Lass N et al. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab. 2011;96(11):3533–40.
37. Vitek W, Hoeger KM. Treatment of polycystic ovary syndrome in adolescence. Semin Reprod Med. 2014;32(3):214–21.
38. Nestler JE et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1989;68(6):1027–32.
39. Nestler JE et al. Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. Am J Obstet Gynecol. 1990;163(4 Pt 1):1243–6.
40. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril. 2007;88(4):886–93.
41. Baillargeon JP et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82(4):893–902.
42. Ibanez L et al. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: Effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab. 2004;89(9):4331–7.
43. Ibanez L et al. Early metformin therapy (age 8–12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011;96(8):E1262–7. This long-term randomized trial (over 7 years) is the first study to show the possibility of preventing PCOS using insulin sensitization in pre-pubertal girls with precocious pubarche who are at high risk to develop PCOS.
44. Carpentier AC. Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes. Diabetes Metab. 2008;34(2):97–107.
45. Mai K et al. Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: A randomized, controlled trial. J Clin Endocrinol Metab. 2008;93(10):3900–6.
46. Bellanger S et al. Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells. Steroids. 2012;77(4):347–53.
47. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep. 2011;11(3):179–84.
48. Manneras-Holm L et al. Adipose tissue has aberrant morphology and function in PCOS: Enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96(2):E304–11.
49. Carmina E et al. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril. 2009;91(4 Suppl):1332–5.
50. Toulis KA et al. Adiponectin levels in women with polycystic ovary syndrome: A systematic review and a meta-analysis. Hum Reprod Update. 2009;15(3):297–307.
51. Kale-Gurbuz T et al. Adiponectin, leptin and ghrelin levels in obese adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2013;26(1):27–30.
52. de Zegher F, Lopez-Bermejo A, Ibanez L. Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab. 2009;20(9):418–23.
53. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373(1–2):29–38.
54. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(2):103–11.
55. Trottier A et al. Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. Fertil Steril. 2012;98(6):1627–34. This study is the first to show that insulin-induced NEFA suppression, insulin sensitivity, and disposition index are significantly impaired in peripubertal girls with a first degree relative known to have PCOS. These results suggest adipose tissue dysfunction and high risk for development of diabetes in adolescents with a first-degree relative with PCOS.
56. Sir-Petermann T et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(6):1923–30.
57. Torchen LC et al. Persistent Apparent Pancreatic beta-Cell Defects in Premenarchal PCOS Relatives. J Clin Endocrinol Metab, 2014: p. jc20141474. This study in pre-menarcheal girls with a first degree relative with PCOS, who were assessed twice over 2 years, evaluated the dynamic changes in insulin secretion and sensitivity over puberty and confirmed that the disposition index was persistently decreased during early puberty in relatives of PCOS. This study also showed increased testosterone levels during the early peripubertal period in these girls.
58. Raissouni N et al. Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome. Int J Pediatr Endocrinol. 2012;2012(1):14.
59. Sir-Petermann T et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(12):4637–42.
60. Goodman E et al. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation. 2007;115(17):2316–22.
61. Cirik DA, Dilbaz B. What do we know about metabolic syndrome in adolescents with PCOS? J Turk Ger Gynecol Assoc. 2014;15(1):49–55.
62. Jolliffe CJ, Janssen I. Development of age-specific adolescent metabolic syndrome criteria that are linked to the Adult Treatment Panel III and International Diabetes Federation criteria. J Am Coll Cardiol. 2007;49(8):891–8.
63. Cook S et al. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J Pediatr. 2008;152(2):165–70.
64. Rossi B et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(12):4780–6.
65. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91(2):492–7.
66. Rahmanpour H et al. Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents. J Pediatr Adolesc Gynecol. 2012;25(3):208–12.
67. Lerchbaum E et al. Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women. Eur J Endocrinol. 2014;170(5):727–39.
68. Weerakiet S et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2001;75(2):177–84.
69. Legro RS et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: A controlled study. J Clin Endocrinol Metab. 2005;90(6):3236–42.
70. Legro RS et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165–9.
71. Ehrmann DA et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–6.
72. Lerchbaum E et al. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod. 2013;28(9):2537–44.
73. Boudreaux MY et al. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep. 2006;6(1):77–83.
74. Talbott EO et al. Polycystic ovarian syndrome (PCOS): A significant contributor to the overall burden of type 2 diabetes in women. J Womens Health (Larchmt). 2007;16(2):191–7.
75. Cowie CC et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–94.
76. Palmert MR et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(3):1017–23.
77. Association, W.H., Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. http://www.who.int. 2006: Geneva.
78. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:3–12.
79. Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ. 2007;176(7):933–8.
80. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001;86(1):66–71.
81. Gooding HC et al. Diagnosing dysglycemia in adolescents with polycystic ovary syndrome. J Adolesc Health. 2014;55(1):79–84.
82. Wild RA et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038–49.
83. Costello M et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;1, CD005552.
84. Tfayli H et al. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: Comparison of metabolic, hormonal, and cardiovascular risk factors. J Clin Endocrinol Metab. 2011;96(5):1311–9.
85. Mastorakos G et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril. 2006;85(2):420–7.
86. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;77(5):919–27.
87. Baillargeon JP et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis. J Clin Endocrinol Metab. 2005;90(7):3863–70.
88. Lidegaard O et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257–66.
89. Salley KE et al. Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546–56.
90. Allen HF et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2005;18(8):761–8.
91. Glueck CJ, Goldenberg N, Wang P. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2009;22(9):815–26.
92. Bridger T et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006;160(3):241–6.
93. Arslanian SA et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87(4):1555–9.
94. Geller DH et al. State of the art review: Emerging therapies: the Use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol. 2011;2011:9.
95. Glueck CJ et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health. 2001;29(3):160–9.
96. De Leo V et al. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod. 2006;21(9):2252–6.
97. Ibanez L et al. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: Additional increments of visfatin and high molecular weight adiponectin. Clin Endocrinol (Oxf). 2008;68(2):317–20.
98. Ibanez L et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab. 2000;85(9):3251–5.
99. Ganie MA et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study. J Clin Endocrinol Metab. 2004;89(6):2756–62.
100. Ibanez L et al. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity. J Clin Endocrinol Metab. 2013;98(5):E902–7. This group published a series of clinical trials on an interesting combination therapy with low-doses of insulin-sensitizers and an antiandrogen in adolescents that showed promising results on improvement of clinical manifestations of PCOS as well as cardiovascular risk factors.